CNV1014802 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Trigeminal Neuralgia
Conditions
Trigeminal Neuralgia
Trial Timeline
Feb 3, 2015 → Apr 20, 2015
NCT ID
NCT02359344About CNV1014802 + Placebo
CNV1014802 + Placebo is a phase 1 stage product being developed by Biogen for Trigeminal Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02359344. Target conditions include Trigeminal Neuralgia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02359344 | Phase 1 | Completed |
| NCT01540630 | Phase 2 | Completed |
| NCT01561027 | Phase 2 | Completed |
Competing Products
7 competing products in Trigeminal Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Approved | 85 |
| Erenumab-Aooe | Amgen | Phase 2 | 51 |
| Rimegepant + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |